Topics:

AIDS-Related Tumors

AIDS-Related Tumors

With National HIV Testing Day recently behind us and the 19th International AIDS conference happening later in July in Washington, DC, I would like to share some recent HIV/AIDS statistical, research, and policy highlights.

We’re now entering the fourth decade of HIV/AIDS awareness. Last year marked the 30th anniversary of the earliest report (on June 5, 1981) of what is now known as AIDS (acquired immune deficiency syndrome).

Thanks to the widespread use of highly active antiretroviral therapy (HAART), AIDS patients continue to live longer after their initial diagnosis.

Though there are no data yet on their efficacy, oleander extracts are promoted to treat cancer, AIDS, and congestive heart failure, and are being investigated in clinical trials.

We cannot escape the realities of biology. Just as children rescued from leukemia and lymphoma live to grow into adults who must confront the adverse effects of their curative treatment, people rescued from AIDS by HAART (highly active antiretroviral therapy) are showing a substantially increased risk of cancers other than the "AIDS-defining" malignancies designated by the Centers for Disease Control in the 1980s: Kaposi sarcoma, non-Hodgkin lymphoma (NHL), and cervical cancer.

HIV’s disruption of immune system function may cause the immune system cells themselves to become cancerous, NCI researchers have concluded. If so, this might explain why patients with AIDS are 100 times more likely to be diagnosed with non-Hodgkin’s lymphoma than the general population.

Malignant pleural effusion complicates the care of approximately 150,000 people in the United States each year. The pleural effusion is usually caused by a disturbance of the normal Starling forces regulating reabsorption of fluid in the pleural space, secondary to obstruction of mediastinal lymph nodes draining the parietal pleura.

Pages

Subscribe to
Please Wait 20 seconds or click here to close